

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  28D0930322	<b>(X3) Date Survey Completed</b>  06/28/2022
<b>Name of Provider or Supplier</b>  Nebraska Hematology Oncology Pc	<b>Street Address, City, State</b>  4004 Pioneer Woods Drive, Lincoln, NE	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on surveyor off-site desk review of the laboratory's 2021 and 2022 College of American Pathologists (CAP) proficiency testing (PT) records and a telephone interview with the laboratory manager on 6/28/2022, it was determined the laboratory failed to achieve satisfactory scores for the hematology analyte prothrombin time. Refer to D2130.</p>
<b>D2130</b>	<p>HEMATOLOGY CFR(s): 493.851(f)</p>

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on off-site desk review of proficiency testing for 2021 and 2022, the laboratory's graded Proficiency Testing results from College of American Pathologists, and interview with the laboratory manager on 6/28/2022 at 8:35 AM, this laboratory had unsatisfactory performance for the analyte prothrombin time in two out of three consecutive testing events. Findings are: 1. 2021 third event, analyte - prothrombin time, score 0%. 2. 2022 second event, analyte - prothrombin time, score 0%.